Last
Update:
September 12, 2007
* Perinatal data are
the Perinatal Data Page
** Pediatric data are in
the Pediatric Data Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
-
PDF POSTER
Genotypic Resistance Analysis in Women Who Received Intrapartum Nevirapine
Associated
to a Short Course of Zidovudine to Prevent Perinatal HIV-1
Transmission: The Ditrame Plus
ANRS 1201/02 Study, Abidjan, Côte d'Ivoire
ML Chaix, C Montcho, DK Ekouevi, et al.
 PDF Poster
Abstract
-
PDF POSTER
Nevirapine Plasma Concentrations Are Still Detectable after More than 2 Weeks in
the
Majority of Women Receiving Single-dose NVP: Implications for Intervention
Studies
E Muro, J Droste, H ter Hofstede, et al
PDF Poster
Abstract-
Toxicity with Continuous Nevirapine in Pregnancy: Results
from PACTG 1022
J Hitti, L Frenkel, S Huang, et al
Abstract
-
Steady State Nevirapine Pharmacokinetics during Second and Third
Trimester Pregnancy
and Postpartum: PACTG 1022
F Aweeka, P Lizak, L Frenkel, et al
Abstract
-
Population Pharmacokinetics of Low-dose Nevirapine for Prevention
of Breast Milk HIV
Transmission in Infants from Birth through 6 Months of Age
M Mirochnick, E Capparelli, Suzette Blanchard, et al
Abstract
-
Adverse Events to Nevirapine Therapy during Pregnancy
J Bershoff-Matcha, LM Mundy, J Henry, et al
Abstract
-
Virologic Failure in Antiretroviral Therapy Naive Patients Is
Only Determined by Extreme
Low Values of CD4+ Cells or High Values of
HIV-1 RNA Concentration, Not by Choice of
Treatment with Nevirapine or Efavirenz
F van Leth, S Andrews, B Grinsztjen, et al
Abstract
-
Nevirapine- vs Efavirenz-based Antiretroviral Treatment in Naive Indian
patients: Comparison of
Effectiveness in a Clinical Cohort
A K Patel, S Pujari, K K PateL et al
Abstract
-
Prevalence of Single Nucleotide Polymorphisms in MDR-1 and CYP3A
Genes
within a
Heterogenous HIV-1-infected Population and Effect on Nevirapine
Plasma
Levels
M van
der Ende, C Sahtoe, J Dieleman, et al
Abstract
|
-
PDF POSTER
Nevirapine And Efavirenz
Have a Comparable Viral Decay Rate Which Is Not Associated
With Virologic
Failure
F Van Leth, C Huisamen, R Badero, et al
 PDF
Poster
Abstract
|
|
-
PDF POSTER
Nevirapine And Efavirenz
Have a Comparable Viral Decay Rate Which Is Not Associated
With Virologic
Failure
 F Van Leth, C Huisamen, R Badero, et al
PDF
Poster
Abstract
-
Long-Term Efficacy and Safety of Protease Inhibitor Switching
to Nevirapine in HIV Patients
with Undetectable Viral Load
Gil P,
Górgolas M, Estrada V, et al.
Abstract
-
THE NIGERIAN ACCELERATED ANTIRETROVIRAL DRUG INITIATIVE- EVALUATION OF
COMBINATION OF NEVIRAPINE (NVP), LAMIVUDINE (3TC), AND STAVUDINE (D4T)
IN
ANTIRETROVIRAL NAIVE PATIENTS
E Ekong, O Akinlade, A Uwah, I Grant-Isibor
Abstract
-
NEVIRAPINE (NVP) SIGNIFICANTLY REDUCES METHADONE LEVELS IN HIV INFECTED
PATIENTS
H. Stocker, G. Kruse, P. Kreckel, et al
Abstract
-
LONG-TERM EFFICACY AND SAFETY OF PROTEASE INHIBITOR SWITCHING TO
NEVIRAPINE
IN HIV PATIENTS WITH UNDETECTABLE VIRAL LOAD
P. Gil, M. Górgolas, V. Estrada, et al
Abstract
-
A
RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY ON EFFECT OF
CETIRIZINE (CET) FOR PREVENTION OF NEVIRAPINE (NVP)-ASSOCIATED RASH. THE
VIZYR TRIAL
O. Launay, L. Roudière, N. Boukli, et al
Abstract
-
SYSTEMATIC REVIEW OF NEVIRAPINE- VERSUS EFAVIRENZ-CONTAINING THREE-
DRUG REGIMENS FOR INITIAL TREATMENT OF HIV INFECTION
MD Neuwelt, O. Bacon, GE. Kennedy, et al
Abstract
-
BENEFIT IN LIPID PROFILE AFTER SWITCHING PROTEASE INHIBITORS TO
NEVIRAPINE
OR EFAVIRENZ: A 48 WEEK STUDY
T. García-Benayas, F. Blanco, J. de la Cruz, et al
Abstract
-
QUALITY OF LIFE IN PATIENTS TREATED WITH FIRST-LINE ANTIRETROVIRAL
THERAPY
CONTAINING NEVIRAPINE AND/OR EFAVIRENZ IN THE 2NN STUDY
F. Van Leth, D. Martin, M. Fisher, et al
Abstract
|
|
-
Long-term efficacy, safety, and tolerability of nevirapine
(NVP)-containing regimens. An
observational study in HIV-1 infected adults
H Eskoetter, T Kaliebe, H Rasokat, H Mielenz
Abstract
-
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a
real-world setting
PC Farrell, P Shalit
Abstract
-
Treatment of tuberculosis (TB) in HIV-infected patients: safety and
antiretroviral
efficacy of concomitant use of nevirapine (NVP) and rifampin (RF)
J Sanz, J Oliva, JA Perez-Molina, et al
Abstract
-
The
role of hepatitis infection and nevirapine on liver abnormalities among
HIV patients
VM Nasiff, M Beltran, R Gil, N Sanga
Abstract
-
Nevirapine clearance after stopping established therapy
GP Taylor, N Tamm, SJ Fidler, J N Weber
Abstract
-
Durability and tolerability of nevirapine-containing regimens in a cohort
of antiretroviral-naïve
HIV-positive patients
NE Mackie, C Sabin, R Weston, J N Weber
Abstract
-
Hypersensitivity skin rash and HIV viral load in patients initiated with
nevirapine
or
abacavir
L Schmid, M Mustafa, H K Thaker, et al
Abstract
-
Patients of Yamanite origin are at increased risk for severe Nevirapine
rash
I Levi, G Regev - Yochai, D Ben David. et al
Abstract
-
Nevirapine prophylaxis for prevention of sexual/blood HIV transmission
in
HIV uninfected
subjects
JB Jackson, S Barnett, L Apuzzo, et al
Abstract
-
Successful antiretroviral prophylaxis with two NRTI’s and a two dose
nevirapine
regime for newborn with a
very high risk of vertical HIV-1 transmission
S Hien, B Buchholz, M Beichert, et al
Abstract
-
Dislipidemia and lipodystrophy associated to ARV treatment based in
Abacavir,
Nevirapine and Efavirenz
AD Alvarado-Diez Rocio, FGM Feregrino-Goyos, RCO Ruiz-Campos Omar,et
al
Abstract
-
Long
term efficacy of nevirapine based triple therapy
RE Greene, D J Ward
Abstract
-
Population pharmacokinetics (PK) of nevirapine (NVP) in an unselected
cohort of HIV-1-
infected individuals
MMR de Maat, ADR Huitema, J Mulder, et al
Abstract -
Nevirapine (NVP) related toxicity after long term Emivirine (EMV) treatment
FM Conradie, P D Ive, W D F Venter, I M Sanne
Abstract
-
Switching protease inhibitors to Nevirapine (NEV), Efavirenz (EFA) or
Abacavir (ABA): A
randomized, multicenter, open-label, simplification trial
E Martinez, D Podzamczer, E Ribera, et
al
Abstract
-
Simplified maintenance therapy with nevirapine: efficacy in actual life
De la Torre, J L Prada, A Del Arco, et al
Abstract
-
Evaluation of toxicity and adverse events related to efavirenz (EFV) and
Nevirapine (NVP)
containning regimens in clinical practice
M Torralba, R Rubio, F Pulido, et al
Abstract
-
Pharmacokinetic of methadone (M) in drug users (DU) taking methadone who
start HAART
with nevirapine
(NVP) once daily
J Portilla, E Arroyo, E Climent, R de la Torre,
et al
Abstract
-
In
vitro studies reveal that zidovudine accelerates the reversion of
nevirapine and
lamivudine resistance confering mutations in the rt gene.
K Diallo, B Brenner, M Oliveira, et al
Abstract
-
A
randomised trial comparing HAART regimens of Nelfinavir/Nevirapine (N/N)
and
Ritonavir/Saquinavir (R/S) in PI and NNRTI naive patients
YO Kirk, J Lundgren, C Pedersen, et al
Abstract -
High
incidence of Nevirapine-associated Hepatotoxicity in Taiwan
SSJ Lee, YS Cheng, W R Lin, et al
Abstract
-
Prospective follow-up of renal function in HIV-infected patients
randomized to combination
antiretroviral therapy including indinavir or nevirapine
P Domingo, M Sambeat, A Arroyo, et al
Abstract
-
An
open label, randomized, comparative trial on the effects of indinavir and
nevirapine on
the lipid profile of HIV-infected patients on combination antiretroviral
therapy
P Domingo, MA Sambeat, JA Arroyo, et al
Abstract
-
Prospective follow-up of liver function tests in HIV-infected patients
randomized to combination antiretroviral therapy including nevirapine or
indinavir
M Gomila, P
Domingo, M A Sambeat, et al
Abstract
-
Effect of combination antiretroviral therapy based on indinavir or
nevirapine on peripheral
blood lymphocyte apoptosis
P Domingo, M A Sambeat, J Arroyo, et al
Abstract
-
A
randomized study of treatment simplification with nevirapine (NVP) or
efavirenz (EFV) in
patients responding to a protease inhibitor (PI) based combination
P Patterson, C Zala, A Krolewiecki, et al
Abstract
-
Hepatic safety of nevirapine: results of the Boehringer Ingelheim
Viramune® Hepatic Safety Project
J Stern, S Lanes, J Love, et al
Abstract
-
ETHNIC AND GENDER DIFFERENCES IN NON-NUCLEOSIDE REVERSE TRANSCRIPTASE
INHIBITOR
(NNRTI) INDUCED RASH
MAZHUDE C, JONES S, TAYLOR C
Abstract
-
GENDER SPECIFIC DIFFERENCES RELATED TO NEVIRAPINE TREATMENT IN HIV-1
INFECTED
DRUG USERS
MIGUEZ-BURBANO M, CASTILLO G, RODRIGUEZ A,
et al
Abstract
-
ANALYSES OF FOUR KEY CLINICAL TRIALS TO ASSESS THE RISK OF HEPATOTOXICITY
WITH
NEVIRAPINE: CORRELATION WITH CD4+ LEVELS, HEPATITIS B& C SEROPOSITIVITY,
AND
BASELINE LIVER FUNCTIONS TESTS.
DIETERICH D, STERN J, ROBINSON P, HALL D, et al
Abstract
-
HEPATIC AND CUTANEOUS TOXICITY ATTRIBUTED TO NEVIRAPINE (NVP)
BENNETT C, JOHNSON S, LYNCH P, et al
Abstract
-
A
RANDOMIZED STUDY OF TREATMENT SIMPLIFICATION WITH NEVIRAPINE (NVP) OR
EFAVIRENZ (EFV) IN PATIENTS RESPONDING TO A PROTEASE INHIBITOR(PI) BASED
COMBINATION.
PATTERSON P, KROLEWIECKI A, OCHOA C, et al
Abstract
-
INITIAL THERAPY WITH NEVIRAPINE- OR PROTEASE INHIBITORS-BASED HAART
THERAPIES:
ONE
YEAR COMPARATIVE OUTCOMES.
PÉREZ-ELIAS M, MORENO A, MORENO S, et al
Abstract
-
DOES
AN INCREASE IN NEVIRAPINE PLASMA LEVELS ALLOW TO REACH COMPLETE
VIROLOGICAL SUPPRESSION IN SUBJECTS WITH EARLY VIROLOGICAL FAILURE?
GONZALEZ-REQUENA D, NUNEZ M, JIMENEZ-NACHER I, et al
Abstract
-
SUSTAINED VIROLOGIC SUPPRESSION IN SUBJECTS SWITCHED FROM PROTEASE
INHIBITORS (PIS) TO NEVIRAPINE (NVP)
IMPERIALE S, CARLIER H
Abstract
-
LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF NEVIRAPINE
(NVP)-CONTAINING
REGIMENS. INTERIM ANALYSIS OF AN OBSERVATIONAL STUDY IN HIV-1 INFECTED
ADULTS
ESKOETTER H, KALIEBE T, RASOKAT H, MIELENZ H. et al
Abstract
-
EXPERIENCE WITH NEVIRAPINE IN COMBINED TREATMENTS
GARCIA MESSINA O, BASES O, JAUREGUI RUEDA H, MONTICHELI A, URIBURU A
Abstract
-
SWITCHING PROTEASE INHIBITOR (PI) TO NEVIRAPINE (NVP) LEADS TO A BETTER
LIPID
PROFILE THAN SWITCH TO EFAVIRENZ (EFV)
IMPERIALE S, CARLIER H
Abstract
-
NUCLEAR MAGNETIC RESONANCE (NMR)-ASSESSED CHANGES OF LIPID METABOLISM (LM)
IN
HIV-1 INFECTED PATIENTS (PTS) WITH LIPODYSTROPHY (LPD) AFTER SWITCHING THE
PROTEASE INHIBITOR (PI) BY NEVIRAPINE (NVP).
NEGREDO E, MASANA L, RIBALTA J, et al
Abstract
-
SWITCHING FROM PROTEASE INHIBITORS TO NEVIRAPINE HAS NO EFFECT ON HAART-
ASSOCIATED SUBCUTANEOUS ADIPOCYTE APOPTOSIS
DOMINGO P, MATIAS-GUIU X, PUJOL R, et al
Abstract
-
NEVIRAPINE-CONTAINING ANTIRETROVIRAL THERAPY IN HIV-1 INFECTED PATIENTS
RESULTS IN AN ANTI-ATHEROGENIC LIPID PROFILE
VAN DER VALK M, KASTELEIN J, MURPHY R, et al
Abstract
|
|
Archived Nevirapine Conference Data B |
| |
11th
CROI
XIV
Int AIDS Conference
Conferences Main Page